Skip to main content
Erschienen in: Cancer Causes & Control 1/2009

01.02.2009 | Original Paper

A population-based, case–control study of green tea consumption and leukemia risk in southwestern Taiwan

verfasst von: Yau-Chang Kuo, Chu-Ling Yu, Chen-Yu Liu, Su-Fen Wang, Pi-Chen Pan, Ming-Tsang Wu, Chi-Kung Ho, Yu-Shing Lo, Yi Li, David C. Christiani, the Kaohsiung Leukemia Research Group

Erschienen in: Cancer Causes & Control | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study investigated the association between green tea consumption and leukemia.

Methods

A total of 252 cases (90.3% response) and 637 controls (53.4% response) were enrolled. Controls were matched for cases on age and gender. Information was collected on participants’ living habits, including tea consumption. Green tea was used as a standard to estimate the total amount of individual catechin consumption. We stratified individual consumption of catechins into four levels. Conditional logistic regression models were fit to subjects aged 0–15 and 16–29 years to evaluate separate associations between leukemia and catechin consumption.

Results

A significant inverse association between green tea consumption and leukemia risk was found in individuals aged 16–29 years, whereas no significant association was found in the younger age groups. For the older group with higher amounts of tea consumption (>550 units of catechins), the adjusted odds ratio (OR) compared with the group without tea consumption was 0.47 [95% confidence interval (CI) = 0.23–0.97]. After we adjusted for smoking status and medical irradiation exposure, the overall OR for all participants was 0.49 (95% CI = 0.27–0.91), indicating an inverse relation between large amounts of catechins and leukemia.

Conclusion

Drinking sufficient amounts of tea, especially green tea, which contains more catechins than oolong tea and black tea, may reduce the risk of leukemia.
Literatur
1.
Zurück zum Zitat Kada T, Kaneko K, Matsuzaki S, Matsuzaki T, Hara Y (1985) Detection and chemical identification of natural bio-antimutagens. A case of the green tea factor. Mutat Res 150(1–2):127–132. doi:10.1016/0027-5107(85)90109-5 PubMed Kada T, Kaneko K, Matsuzaki S, Matsuzaki T, Hara Y (1985) Detection and chemical identification of natural bio-antimutagens. A case of the green tea factor. Mutat Res 150(1–2):127–132. doi:10.​1016/​0027-5107(85)90109-5 PubMed
3.
4.
Zurück zum Zitat Zhang Q, Tang X, Lu Q, Zhang Z, Rao J, Le AD (2006) Green tea extract and (−)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther 5(5):1227–1238. doi:10.1158/1535-7163.MCT-05-0490 PubMedCrossRef Zhang Q, Tang X, Lu Q, Zhang Z, Rao J, Le AD (2006) Green tea extract and (−)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther 5(5):1227–1238. doi:10.​1158/​1535-7163.​MCT-05-0490 PubMedCrossRef
5.
Zurück zum Zitat Mukhtar H (1994) Cancer chemoprevention by green tea components. Adv Exp Med Biol 354:123–134PubMed Mukhtar H (1994) Cancer chemoprevention by green tea components. Adv Exp Med Biol 354:123–134PubMed
7.
Zurück zum Zitat Michels KB, Mohllajee AP, Roset-Bahmanyar E, Beehler GP, Moysich KB (2007) Diet and breast cancer: a review of the prospective observational studies. Cancer 109(12):2712–2749. doi:10.1002/cncr.22654 PubMedCrossRef Michels KB, Mohllajee AP, Roset-Bahmanyar E, Beehler GP, Moysich KB (2007) Diet and breast cancer: a review of the prospective observational studies. Cancer 109(12):2712–2749. doi:10.​1002/​cncr.​22654 PubMedCrossRef
8.
Zurück zum Zitat Jian L, Lee AH, Binns CW (2007) Tea and lycopene protect against prostate cancer. Asia Pac J Clin Nutr 16(1):453–457PubMed Jian L, Lee AH, Binns CW (2007) Tea and lycopene protect against prostate cancer. Asia Pac J Clin Nutr 16(1):453–457PubMed
9.
Zurück zum Zitat Wang JM, Xu B, Rao JY, Shen HB, Xue HC, Jiang QW (2007) Diet habits, alcohol drinking, tobacco smoking, green tea drinking, and the risk of esophageal squamous cell carcinoma in the Chinese population. Eur J Gastroenterol Hepatol 19(2):171–176. doi:10.1097/MEG.0b013e32800ff77a PubMedCrossRef Wang JM, Xu B, Rao JY, Shen HB, Xue HC, Jiang QW (2007) Diet habits, alcohol drinking, tobacco smoking, green tea drinking, and the risk of esophageal squamous cell carcinoma in the Chinese population. Eur J Gastroenterol Hepatol 19(2):171–176. doi:10.​1097/​MEG.​0b013e32800ff77a​ PubMedCrossRef
12.
Zurück zum Zitat Zhang XH, Andreotti G, Gao YT et al (2006) Tea drinking and the risk of biliary tract cancers and biliary stones: a population-based case–control study in Shanghai, China. Int J Cancer 118(12):3089–3094. doi:10.1002/ijc.21748 PubMedCrossRef Zhang XH, Andreotti G, Gao YT et al (2006) Tea drinking and the risk of biliary tract cancers and biliary stones: a population-based case–control study in Shanghai, China. Int J Cancer 118(12):3089–3094. doi:10.​1002/​ijc.​21748 PubMedCrossRef
14.
Zurück zum Zitat Linet MS (1996) Leukemias. In: Harras A (ed) Cancer rates and risks, 4th edn. National Cancer Institute, Bethesda, MD Linet MS (1996) Leukemias. In: Harras A (ed) Cancer rates and risks, 4th edn. National Cancer Institute, Bethesda, MD
15.
Zurück zum Zitat Linet MS, Cartwright RA (1996) The leukemias. Oxford University Press, New York, NY Linet MS, Cartwright RA (1996) The leukemias. Oxford University Press, New York, NY
16.
Zurück zum Zitat Miller R et al (1996) Childhood. In: Harras A (ed) Cancer rates and risks, 4th edn. National Cancer Institute, Bethesda, MD Miller R et al (1996) Childhood. In: Harras A (ed) Cancer rates and risks, 4th edn. National Cancer Institute, Bethesda, MD
17.
Zurück zum Zitat Yu CL, Wang SF, Pan PC et al (2006) Residential exposure to petrochemicals and the risk of leukemia: using geographic information system tools to estimate individual-level residential exposure. Am J Epidemiol 164(3):200–207. doi:10.1093/aje/kwj182 PubMedCrossRef Yu CL, Wang SF, Pan PC et al (2006) Residential exposure to petrochemicals and the risk of leukemia: using geographic information system tools to estimate individual-level residential exposure. Am J Epidemiol 164(3):200–207. doi:10.​1093/​aje/​kwj182 PubMedCrossRef
19.
Zurück zum Zitat Dreosti IE (1996) Bioactive ingredients: antioxidants and polyphenols in tea. Nutr Rev 54:S51–S58PubMedCrossRef Dreosti IE (1996) Bioactive ingredients: antioxidants and polyphenols in tea. Nutr Rev 54:S51–S58PubMedCrossRef
26.
Zurück zum Zitat Smith DM, Dou OP (2001) Green tea polyphenol epigallocatechin inhibits DNA replication and consequently induces leukemia cell apoptosis. Int J Mol Med 7(6):645–652PubMed Smith DM, Dou OP (2001) Green tea polyphenol epigallocatechin inhibits DNA replication and consequently induces leukemia cell apoptosis. Int J Mol Med 7(6):645–652PubMed
28.
Zurück zum Zitat Bushman JL (1998) Green tea and cancer in humans: a review of the literature. Nutr Cancer 31:151–159PubMedCrossRef Bushman JL (1998) Green tea and cancer in humans: a review of the literature. Nutr Cancer 31:151–159PubMedCrossRef
29.
Zurück zum Zitat Annabi B, Currie JC, Moghrabi A, Beliveau R (2006) Inhibition of HuR and MMP-9 expression in macrophage-differentiated HL-60 myeloid leukemia cells by green tea polyphenol EGCg. Leuk Res 31(9):1277–1284PubMedCrossRef Annabi B, Currie JC, Moghrabi A, Beliveau R (2006) Inhibition of HuR and MMP-9 expression in macrophage-differentiated HL-60 myeloid leukemia cells by green tea polyphenol EGCg. Leuk Res 31(9):1277–1284PubMedCrossRef
30.
Zurück zum Zitat Komori A, Yatsunami J, Okabe S et al (1993) Anticarcinogenic activity of green tea polyphenols. Jpn J Clin Oncolo 23:186–190 Komori A, Yatsunami J, Okabe S et al (1993) Anticarcinogenic activity of green tea polyphenols. Jpn J Clin Oncolo 23:186–190
32.
Zurück zum Zitat Ng KK, Miller VA, Grant SC et al. (1999) Phase I and clinical pharmacologic study of green tea extract (GTE) in patients with advanced solid tumors (ASCO). Am Soc Clinical Oncology Meeting abstract #853 Ng KK, Miller VA, Grant SC et al. (1999) Phase I and clinical pharmacologic study of green tea extract (GTE) in patients with advanced solid tumors (ASCO). Am Soc Clinical Oncology Meeting abstract #853
33.
Zurück zum Zitat Rothman KJ, Green IS (1998) Modern epidemiology. Lippincott-Raven, Philadelphia, PA Rothman KJ, Green IS (1998) Modern epidemiology. Lippincott-Raven, Philadelphia, PA
Metadaten
Titel
A population-based, case–control study of green tea consumption and leukemia risk in southwestern Taiwan
verfasst von
Yau-Chang Kuo
Chu-Ling Yu
Chen-Yu Liu
Su-Fen Wang
Pi-Chen Pan
Ming-Tsang Wu
Chi-Kung Ho
Yu-Shing Lo
Yi Li
David C. Christiani
the Kaohsiung Leukemia Research Group
Publikationsdatum
01.02.2009
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 1/2009
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9217-7

Weitere Artikel der Ausgabe 1/2009

Cancer Causes & Control 1/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.